Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyAminophylline
Targets (4)
Enzymes (3)
Identification
- Name
- Aminophylline
- Accession Number
- DB01223 (APRD00329)
- Type
- Small Molecule
- Groups
- Approved
- Description
Aminophylline is a drug combination that contains theophylline and ethylenediamine in a 2:1 ratio. Once in the body, theophylline is released and acts as a phosphodiesterase inhibitor, adenosine receptor blocker, and histone deacetylase activator. Similar to other theophyllines, aminophylline is indicated for the treatment of lung diseases such as asthma, chronic bronchitis, and COPD. The majority of aminophylline medications are discontinued and the remaining medications on the market are in short supply.
- Structure
Structure for DB01223 (Aminophylline)
- Synonyms
- Aminophyllin
- Somophyllin
- Theophylline ethylenediamine
- External IDs
- Not Available
- Product Ingredients
Ingredient UNII CAS InChI Key Aminophylline dihydrate C229N9DX94 5897-66-5 FXNJPZOEDHBGEY-UHFFFAOYSA-N - Approved Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Aminophylline Inj 25mg/ml Liquid 25 mg Intravenous Abbott 1985-12-31 1997-08-18 Canada 
Aminophylline Inj 25mg/ml Solution 25 mg Intravenous Omega Laboratories Ltd 1984-12-31 Not applicable Canada Aminophylline Inj 50mg/ml Solution 50 mg Intravenous Omega Laboratories Ltd 1984-12-31 Not applicable Canada Aminophylline Injection 50mg/ml Solution 50 mg Intravenous Hospira, Inc. 1981-12-31 2012-08-03 Canada Aminophylline Tab 0.1gm Tablet 100 mg Oral Lederle Cyanamid Canada Inc. 1951-12-31 2000-08-02 Canada Aminophylline Tab 100mg Tablet 97.5 mg Oral Stanley Pharmaceuticals, A Division Of Vita Health Products Inc. 1957-12-31 2002-07-31 Canada Jaa Aminophylline Tab 100mg Tablet 100 mg Oral Jaapharm Canada Inc. 1993-12-31 2016-08-10 Canada Phyllocontin Tablet, extended release 225 mg Oral Purdue Pharma 1993-12-31 2011-08-04 Canada Phyllocontin-350 Tablet, extended release 350 mg Oral Purdue Pharma 1993-12-31 2011-08-04 Canada - Approved Generic Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Aminophylline Tablet 100 mg/1 Oral West Ward Pharmaceutical 1975-11-26 Not applicable US 
Aminophylline Injection, solution 25 mg/mL Intravenous General Injectables & Vaccines 2009-01-01 Not applicable US Aminophylline Injection, solution 25 mg/mL Intravenous Cardinal Health 2011-02-11 Not applicable US Aminophylline Injection, solution 25 mg/mL Intravenous Hospira, Inc. 1983-10-26 Not applicable US Aminophylline Tablet 200 mg/1 Oral West Ward Pharmaceutical 1976-05-28 Not applicable US Aminophylline Injection, solution 25 mg/mL Intravenous Hospira, Inc. 1983-10-26 Not applicable US Aminophylline Injection, solution 25 mg/mL Intravenous Hospira, Inc. 1983-10-26 Not applicable US Aminophylline Injection, solution 25 mg/mL Intravenous General Injectables & Vaccines 2010-07-01 Not applicable US Aminophylline Injection, solution 25 mg/mL Intravenous Cardinal Health 2011-02-11 Not applicable US Aminophylline Injection, solution 25 mg/mL Intravenous Hospira, Inc. 1983-10-26 Not applicable US - Approved Over the Counter Products
- Not Available
- Unapproved/Other Products
- Not Available
- International/Other Brands
- Minomal / Somophyllin / Truphylline
- Brand mixtures
- Not Available
- Categories
- Alkaloids
- Amines
- Anti-Asthmatic Agents
- Autonomic Agents
- Bronchodilator Agents
- Cardiotonic Agents
- Cardiovascular Agents
- Cytochrome P-450 CYP1A2 Inhibitors
- Cytochrome P-450 CYP1A2 Inhibitors (weak)
- Cytochrome P-450 CYP1A2 Substrates
- Cytochrome P-450 CYP2E1 Substrates
- Cytochrome P-450 CYP3A4 Substrates
- Diamines
- Drugs for Obstructive Airway Diseases
- Enzyme Inhibitors
- Ethylenediamines
- Neurotransmitter Agents
- Peripheral Nervous System Agents
- Pharmaceutical Preparations
- Phosphodiesterase Inhibitors
- Polyamines
- Protective Agents
- Purinergic Agents
- Purinergic Antagonists
- Purinergic P1 Receptor Antagonists
- Purines
- Purinones
- Respiratory System Agents
- Theophylline
- Theophylline Derivatives
- Xanthines
- UNII
- 27Y3KJK423
- CAS number
- 317-34-0
- Weight
- Average: 420.4264
Monoisotopic: 420.198199306 - Chemical Formula
- C16H24N10O4
- InChI Key
- FQPFAHBPWDRTLU-UHFFFAOYSA-N
- InChI
- InChI=1S/2C7H8N4O2.C2H8N2/c2*1-10-5-4(8-3-9-5)6(12)11(2)7(10)13;3-1-2-4/h2*3H,1-2H3,(H,8,9);1-4H2
- IUPAC Name
- bis(1,3-dimethyl-2,3,6,7-tetrahydro-1H-purine-2,6-dione); ethane-1,2-diamine
- SMILES
- NCCN.CN1C2=C(NC=N2)C(=O)N(C)C1=O.CN1C2=C(NC=N2)C(=O)N(C)C1=O
Pharmacology
- Indication
For the treatment of bronchospasm due to asthma, emphysema and chronic bronchitis.
- Structured Indications
- Pharmacodynamics
Aminophylline is the ethylenediamine salt of theophylline. Theophylline stimulates the CNS, skeletal muscles, and cardiac muscle. It relaxes certain smooth muscles in the bronchi, produces diuresis, and causes an increase in gastric secretion.
- Mechanism of action
Aminophylline is the ethylenediamine salt of theophylline. After ingestion, theophylline is released from aminophylline, and theophylline relaxes the smooth muscle of the bronchial airways and pulmonary blood vessels and reduces airway responsiveness to histamine, methacholine, adenosine, and allergen. Theophylline competitively inhibits type III and type IV phosphodiesterase (PDE), the enzyme responsible for breaking down cyclic AMP in smooth muscle cells, possibly resulting in bronchodilation. Theophylline also binds to the adenosine A2B receptor and blocks adenosine mediated bronchoconstriction. In inflammatory states, theophylline activates histone deacetylase to prevent transcription of inflammatory genes that require the acetylation of histones for transcription to begin.
Target Actions Organism AcGMP-inhibited 3',5'-cyclic phosphodiesterase A inhibitorHuman AAdenosine receptor A1 antagonistHuman AAdenosine receptor A3 antagonistHuman AHistone deacetylase 2 activatorHuman - Absorption
- Not Available
- Volume of distribution
- 0.3 to 0.7 L/kg
- Protein binding
60%
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half life
7-9 hours
- Clearance
- 0.29 mL/kg/min [postnatal age 3-15 days]
- 0.64 mL/kg/min [postnatal age 25-57 days]
- 1.7 mL/kg/min [ 1-4 years]
- 1.6 mL/kg/min [4-12 years]
- 0.9 mL/kg/min [13-15 years]
- 1.4 mL/kg/min [16-17 years]
- 0.65 mL/kg/min [Adults (16-60 years), non-smoking asthmatics]
- 0.41 mL/kg/min [Elderly (>60 years). liver, and renal function]
- 0.33 mL/kg/min [Acute pulmonary edema]
- 0.54 mL/kg/min [COPD->60 years, stable non-smoker >1 year]
- 0.48 mL/kg/min [COPD with cor pulmonale]
- 1.25 mL/kg/min [Cystic fibrosis (14-28 years)]
- 0.31 mL/kg/min [Liver disease -cholestasis]
- 0.35 mL/kg/min [cirrhosis]
- 0.65 mL/kg/min [acute hepatitis]
- 0.47 mL/kg/min [Sepsis with multi-organ failure]
- 0.38 mL/kg/min [hypothyroid]
- 0.8 mL/kg/min [hyperthyroid]
- Toxicity
- Not Available
- Affected organisms
- Humans and other mammals
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction Drug group 1,10-Phenanthroline The serum concentration of Aminophylline can be decreased when it is combined with 1,10-Phenanthroline. Experimental 3,4-Dichloroisocoumarin The serum concentration of Aminophylline can be decreased when it is combined with 3,4-Dichloroisocoumarin. Experimental 4-(2-Aminoethyl)Benzenesulfonyl Fluoride The serum concentration of Aminophylline can be decreased when it is combined with 4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDE. Experimental Abiraterone The serum concentration of Aminophylline can be increased when it is combined with Abiraterone. Approved Acebutolol Acebutolol may decrease the bronchodilatory activities of Aminophylline. Approved Adalimumab The serum concentration of Aminophylline can be decreased when it is combined with Adalimumab. Approved Adenosine The therapeutic efficacy of Adenosine can be decreased when used in combination with Aminophylline. Approved, Investigational Albinterferon Alfa-2B The metabolism of Aminophylline can be decreased when combined with Albumin-interferon alpha. Investigational Allopurinol The serum concentration of Aminophylline can be increased when it is combined with Allopurinol. Approved Alogliptin The serum concentration of Aminophylline can be decreased when it is combined with Alogliptin. Approved Alpha-1-proteinase inhibitor The serum concentration of Aminophylline can be decreased when it is combined with Alpha-1-proteinase inhibitor. Approved Alprazolam The therapeutic efficacy of Alprazolam can be decreased when used in combination with Aminophylline. Approved, Illicit, Investigational Alprenolol Alprenolol may decrease the bronchodilatory activities of Aminophylline. Approved, Withdrawn Amiodarone The metabolism of Aminophylline can be decreased when combined with Amiodarone. Approved, Investigational Amobarbital The serum concentration of Aminophylline can be decreased when it is combined with Amobarbital. Approved, Illicit Amprenavir The serum concentration of Aminophylline can be decreased when it is combined with Amprenavir. Approved Antithrombin III human The serum concentration of Aminophylline can be decreased when it is combined with Antithrombin III human. Approved Apixaban The serum concentration of Aminophylline can be decreased when it is combined with Apixaban. Approved Aprepitant The serum concentration of Aminophylline can be increased when it is combined with Aprepitant. Approved, Investigational Aprotinin The serum concentration of Aminophylline can be decreased when it is combined with Aprotinin. Approved, Withdrawn Argatroban The serum concentration of Aminophylline can be decreased when it is combined with Argatroban. Approved, Investigational Asunaprevir The serum concentration of Aminophylline can be decreased when it is combined with Asunaprevir. Approved, Investigational Atazanavir The metabolism of Aminophylline can be decreased when combined with Atazanavir. Approved, Investigational Atenolol Atenolol may decrease the bronchodilatory activities of Aminophylline. Approved Atomoxetine The metabolism of Aminophylline can be decreased when combined with Atomoxetine. Approved Azithromycin The metabolism of Aminophylline can be decreased when combined with Azithromycin. Approved Barbexaclone The serum concentration of Aminophylline can be decreased when it is combined with Barbexaclone. Experimental Barbital The serum concentration of Aminophylline can be decreased when it is combined with Barbital. Illicit Batimastat The serum concentration of Aminophylline can be decreased when it is combined with Batimastat. Experimental Bazedoxifene The serum concentration of Aminophylline can be increased when it is combined with Bazedoxifene. Approved, Investigational Benazepril The serum concentration of Aminophylline can be decreased when it is combined with Benazepril. Approved, Investigational Benzamidine The serum concentration of Aminophylline can be decreased when it is combined with Benzamidine. Experimental Betaxolol Betaxolol may decrease the bronchodilatory activities of Aminophylline. Approved Bexarotene The serum concentration of Aminophylline can be decreased when it is combined with Bexarotene. Approved, Investigational Bisoprolol Bisoprolol may decrease the bronchodilatory activities of Aminophylline. Approved Bivalirudin The serum concentration of Aminophylline can be decreased when it is combined with Bivalirudin. Approved, Investigational Boceprevir The metabolism of Aminophylline can be decreased when combined with Boceprevir. Withdrawn Bopindolol Bopindolol may decrease the bronchodilatory activities of Aminophylline. Approved Bortezomib The metabolism of Aminophylline can be decreased when combined with Bortezomib. Approved, Investigational Bosentan The serum concentration of Aminophylline can be decreased when it is combined with Bosentan. Approved, Investigational Bromazepam The therapeutic efficacy of Bromazepam can be decreased when used in combination with Aminophylline. Approved, Illicit Bupranolol Bupranolol may decrease the bronchodilatory activities of Aminophylline. Approved Caffeine The metabolism of Aminophylline can be decreased when combined with Caffeine. Approved Camazepam The therapeutic efficacy of Camazepam can be decreased when used in combination with Aminophylline. Approved, Illicit Candoxatril The serum concentration of Aminophylline can be decreased when it is combined with Candoxatril. Experimental Candoxatrilat The serum concentration of Aminophylline can be decreased when it is combined with Candoxatrilat. Experimental Captopril The serum concentration of Aminophylline can be decreased when it is combined with Captopril. Approved Carbamazepine The serum concentration of Aminophylline can be decreased when it is combined with Carbamazepine. Approved, Investigational Carbimazole The serum concentration of Aminophylline can be increased when it is combined with Carbimazole. Approved Carbomycin The metabolism of Aminophylline can be decreased when combined with Carbomycin. Vet Approved Carteolol Carteolol may decrease the bronchodilatory activities of Aminophylline. Approved Celiprolol Celiprolol may decrease the bronchodilatory activities of Aminophylline. Approved, Investigational Ceritinib The serum concentration of Aminophylline can be increased when it is combined with Ceritinib. Approved Chlordiazepoxide The therapeutic efficacy of Chlordiazepoxide can be decreased when used in combination with Aminophylline. Approved, Illicit Chlorotrianisene The serum concentration of Aminophylline can be increased when it is combined with Chlorotrianisene. Withdrawn Chymostatin The serum concentration of Aminophylline can be decreased when it is combined with Chymostatin. Experimental Cilastatin The serum concentration of Aminophylline can be decreased when it is combined with Cilastatin. Approved Cilazapril The serum concentration of Aminophylline can be decreased when it is combined with Cilazapril. Approved Cimetidine The metabolism of Aminophylline can be decreased when combined with Cimetidine. Approved Cinoxacin The metabolism of Aminophylline can be decreased when combined with Cinoxacin. Approved, Withdrawn Ciprofloxacin The metabolism of Aminophylline can be decreased when combined with Ciprofloxacin. Approved, Investigational Citalopram The metabolism of Aminophylline can be decreased when combined with Citalopram. Approved Clarithromycin The metabolism of Aminophylline can be decreased when combined with Clarithromycin. Approved Clemastine The metabolism of Aminophylline can be decreased when combined with Clemastine. Approved Clonazepam The therapeutic efficacy of Clonazepam can be decreased when used in combination with Aminophylline. Approved, Illicit Clorazepate The therapeutic efficacy of Clorazepate can be decreased when used in combination with Aminophylline. Approved, Illicit Clotrimazole The metabolism of Aminophylline can be decreased when combined with Clotrimazole. Approved, Vet Approved Cobicistat The metabolism of Aminophylline can be decreased when combined with Cobicistat. Approved Conivaptan The serum concentration of Aminophylline can be increased when it is combined with Conivaptan. Approved, Investigational Conjugated estrogens The serum concentration of Aminophylline can be increased when it is combined with Conjugated Equine Estrogens. Approved Crizotinib The metabolism of Aminophylline can be decreased when combined with Crizotinib. Approved Cyclosporine The metabolism of Aminophylline can be decreased when combined with Cyclosporine. Approved, Investigational, Vet Approved Cyproterone acetate The serum concentration of Aminophylline can be decreased when it is combined with Cyproterone acetate. Approved, Investigational Dabigatran etexilate The serum concentration of Aminophylline can be decreased when it is combined with Dabigatran etexilate. Approved Dabrafenib The serum concentration of Aminophylline can be decreased when it is combined with Dabrafenib. Approved Darexaban The serum concentration of Aminophylline can be decreased when it is combined with Ym150. Investigational Darunavir The metabolism of Aminophylline can be decreased when combined with Darunavir. Approved Dasatinib The serum concentration of Aminophylline can be increased when it is combined with Dasatinib. Approved, Investigational Deferasirox The serum concentration of Aminophylline can be decreased when it is combined with Deferasirox. Approved, Investigational Delavirdine The metabolism of Aminophylline can be decreased when combined with Delavirdine. Approved Delorazepam The therapeutic efficacy of Delorazepam can be decreased when used in combination with Aminophylline. Approved, Illicit Dexamethasone The serum concentration of Aminophylline can be decreased when it is combined with Dexamethasone. Approved, Investigational, Vet Approved Diazepam The therapeutic efficacy of Diazepam can be decreased when used in combination with Aminophylline. Approved, Illicit, Vet Approved Dienestrol The serum concentration of Aminophylline can be increased when it is combined with Dienestrol. Approved Diethylstilbestrol The serum concentration of Aminophylline can be increased when it is combined with Diethylstilbestrol. Approved Dihydroergotamine The metabolism of Aminophylline can be decreased when combined with Dihydroergotamine. Approved Diltiazem The metabolism of Aminophylline can be decreased when combined with Diltiazem. Approved Disulfiram The serum concentration of Aminophylline can be increased when it is combined with Disulfiram. Approved Doxofylline The risk or severity of adverse effects can be increased when Aminophylline is combined with Doxofylline. Approved Doxycycline The metabolism of Aminophylline can be decreased when combined with Doxycycline. Approved, Investigational, Vet Approved Dronedarone The metabolism of Aminophylline can be decreased when combined with Dronedarone. Approved Ecabet The serum concentration of Aminophylline can be decreased when it is combined with Ecabet. Approved, Investigational Edoxaban The serum concentration of Aminophylline can be decreased when it is combined with Edoxaban. Approved Efavirenz The serum concentration of Aminophylline can be decreased when it is combined with Efavirenz. Approved, Investigational Elafin The serum concentration of Aminophylline can be decreased when it is combined with Elafin. Investigational Enalapril The serum concentration of Aminophylline can be decreased when it is combined with Enalapril. Approved, Vet Approved Enalaprilat The serum concentration of Aminophylline can be decreased when it is combined with Enalaprilat. Approved Enalkiren The serum concentration of Aminophylline can be decreased when it is combined with Enalkiren. Experimental Enoxacin The metabolism of Aminophylline can be decreased when combined with Enoxacin. Approved Enzalutamide The serum concentration of Aminophylline can be decreased when it is combined with Enzalutamide. Approved Equol The serum concentration of Aminophylline can be increased when it is combined with S Equol. Investigational Erythromycin The metabolism of Aminophylline can be decreased when combined with Erythromycin. Approved, Vet Approved Eslicarbazepine acetate The serum concentration of Aminophylline can be decreased when it is combined with Eslicarbazepine acetate. Approved Esmolol Esmolol may decrease the bronchodilatory activities of Aminophylline. Approved Estazolam The therapeutic efficacy of Estazolam can be decreased when used in combination with Aminophylline. Approved, Illicit Estradiol The serum concentration of Aminophylline can be increased when it is combined with Estradiol. Approved, Investigational, Vet Approved Estriol The serum concentration of Aminophylline can be increased when it is combined with Estriol. Approved, Vet Approved Estrone The serum concentration of Aminophylline can be increased when it is combined with Estrone. Approved Ethanol The serum concentration of Aminophylline can be increased when it is combined with Ethanol. Approved Ethinyl Estradiol The serum concentration of Aminophylline can be increased when it is combined with Ethinyl Estradiol. Approved Etizolam The therapeutic efficacy of Etizolam can be decreased when used in combination with Aminophylline. Approved Etravirine The serum concentration of Aminophylline can be decreased when it is combined with Etravirine. Approved Faldaprevir The serum concentration of Aminophylline can be decreased when it is combined with Bi201335. Investigational Febuxostat The serum concentration of the active metabolites of Aminophylline can be increased when Aminophylline is used in combination with Febuxostat. Approved Fleroxacin The metabolism of Aminophylline can be decreased when combined with Fleroxacin. Approved Fluconazole The metabolism of Aminophylline can be decreased when combined with Fluconazole. Approved Fludiazepam The therapeutic efficacy of Fludiazepam can be decreased when used in combination with Aminophylline. Approved, Illicit Flumazenil The therapeutic efficacy of Flumazenil can be decreased when used in combination with Aminophylline. Approved Flumequine The metabolism of Aminophylline can be decreased when combined with Flumequine. Withdrawn Flunitrazepam The therapeutic efficacy of Flunitrazepam can be decreased when used in combination with Aminophylline. Approved, Illicit Flurazepam The therapeutic efficacy of Flurazepam can be decreased when used in combination with Aminophylline. Approved, Illicit Fluvoxamine The metabolism of Aminophylline can be decreased when combined with Fluvoxamine. Approved, Investigational Formoterol The risk or severity of adverse effects can be increased when Aminophylline is combined with Formoterol. Approved, Investigational Fosamprenavir The metabolism of Aminophylline can be decreased when combined with Fosamprenavir. Approved Fosaprepitant The serum concentration of Aminophylline can be increased when it is combined with Fosaprepitant. Approved Fosinopril The serum concentration of Aminophylline can be decreased when it is combined with Fosinopril. Approved Fosphenytoin The serum concentration of Aminophylline can be decreased when it is combined with Fosphenytoin. Approved Fusidic Acid The serum concentration of Aminophylline can be increased when it is combined with Fusidic Acid. Approved Gabexate The serum concentration of Aminophylline can be decreased when it is combined with Gabexate. Investigational Garenoxacin The metabolism of Aminophylline can be decreased when combined with Garenoxacin. Investigational Gatifloxacin The metabolism of Aminophylline can be decreased when combined with Gatifloxacin. Approved, Investigational Geldanamycin The serum concentration of Aminophylline can be decreased when it is combined with Geldanamycin. Experimental Gemifloxacin The metabolism of Aminophylline can be decreased when combined with Gemifloxacin. Approved, Investigational Genistein The serum concentration of Aminophylline can be increased when it is combined with Genistein. Investigational GM6001 The serum concentration of Aminophylline can be decreased when it is combined with GM6001. Experimental Grepafloxacin The metabolism of Aminophylline can be decreased when combined with Grepafloxacin. Withdrawn Hexestrol The serum concentration of Aminophylline can be increased when it is combined with Hexestrol. Withdrawn Hexobarbital The serum concentration of Aminophylline can be decreased when it is combined with Hexobarbital. Approved Idelalisib The serum concentration of Aminophylline can be increased when it is combined with Idelalisib. Approved Idraparinux The serum concentration of Aminophylline can be decreased when it is combined with idraparinux. Investigational IFNa The metabolism of Aminophylline can be decreased when combined with IFNa. Investigational Imatinib The metabolism of Aminophylline can be decreased when combined with Imatinib. Approved Imidapril The serum concentration of Aminophylline can be decreased when it is combined with Imidapril. Investigational Indacaterol The risk or severity of adverse effects can be increased when Aminophylline is combined with Indacaterol. Approved Indinavir The metabolism of Aminophylline can be decreased when combined with Indinavir. Approved Interferon Alfa-2a, Recombinant The metabolism of Aminophylline can be decreased when combined with Interferon Alfa-2a, Recombinant. Approved Interferon Alfa-2b, Recombinant The metabolism of Aminophylline can be decreased when combined with Interferon Alfa-2b, Recombinant. Approved Interferon alfa-n1 The metabolism of Aminophylline can be decreased when combined with Interferon alfa-n1. Approved Interferon alfa-n3 The metabolism of Aminophylline can be decreased when combined with Interferon alfa-n3. Approved, Investigational Interferon alfacon-1 The metabolism of Aminophylline can be decreased when combined with Interferon alfacon-1. Approved Interferon beta-1a The metabolism of Aminophylline can be decreased when combined with Interferon beta-1a. Approved, Investigational Interferon beta-1b The metabolism of Aminophylline can be decreased when combined with Interferon beta-1b. Approved Interferon gamma-1b The metabolism of Aminophylline can be decreased when combined with Interferon gamma-1b. Approved, Investigational Isavuconazonium The metabolism of Aminophylline can be decreased when combined with Isavuconazonium. Approved, Investigational Isoflurophate The serum concentration of Aminophylline can be decreased when it is combined with Isoflurophate. Approved, Withdrawn Isoniazid The serum concentration of Aminophylline can be increased when it is combined with Isoniazid. Approved Isoprenaline The serum concentration of Aminophylline can be decreased when it is combined with Isoprenaline. Approved Isradipine The metabolism of Aminophylline can be decreased when combined with Isradipine. Approved Itraconazole The metabolism of Aminophylline can be decreased when combined with Itraconazole. Approved, Investigational Ivacaftor The serum concentration of Aminophylline can be increased when it is combined with Ivacaftor. Approved Ixazomib The serum concentration of Aminophylline can be decreased when it is combined with Ixazomib. Approved Josamycin The metabolism of Aminophylline can be decreased when combined with Josamycin. Approved Ketoconazole The metabolism of Aminophylline can be decreased when combined with Ketoconazole. Approved, Investigational Kitasamycin The metabolism of Aminophylline can be decreased when combined with Kitasamycin. Experimental Lepirudin The serum concentration of Aminophylline can be decreased when it is combined with Lepirudin. Approved Levofloxacin The metabolism of Aminophylline can be decreased when combined with Levofloxacin. Approved, Investigational Levothyroxine The metabolism of Aminophylline can be increased when combined with Levothyroxine. Approved Lidocaine The metabolism of Aminophylline can be decreased when combined with Lidocaine. Approved, Vet Approved Linagliptin The serum concentration of Aminophylline can be decreased when it is combined with Linagliptin. Approved Liothyronine The metabolism of Aminophylline can be increased when combined with Liothyronine. Approved, Vet Approved Liotrix The metabolism of Aminophylline can be increased when combined with Liotrix. Approved Lisinopril The serum concentration of Aminophylline can be decreased when it is combined with Lisinopril. Approved, Investigational Lithium The serum concentration of Lithium can be decreased when it is combined with Aminophylline. Approved Lomefloxacin The metabolism of Aminophylline can be decreased when combined with Lomefloxacin. Approved Lopinavir The metabolism of Aminophylline can be decreased when combined with Lopinavir. Approved Lorazepam The therapeutic efficacy of Lorazepam can be decreased when used in combination with Aminophylline. Approved Lovastatin The metabolism of Aminophylline can be decreased when combined with Lovastatin. Approved, Investigational Luliconazole The serum concentration of Aminophylline can be increased when it is combined with Luliconazole. Approved Lumacaftor The metabolism of Aminophylline can be increased when combined with Lumacaftor. Approved Mestranol The serum concentration of Aminophylline can be increased when it is combined with Mestranol. Approved Methallenestril The serum concentration of Aminophylline can be increased when it is combined with Methallenestril. Experimental Methimazole The serum concentration of Aminophylline can be increased when it is combined with Methimazole. Approved Methohexital The serum concentration of Aminophylline can be decreased when it is combined with Methohexital. Approved Methotrexate The serum concentration of Aminophylline can be increased when it is combined with Methotrexate. Approved Methylphenobarbital The serum concentration of Aminophylline can be decreased when it is combined with Methylphenobarbital. Approved Metoprolol Metoprolol may decrease the bronchodilatory activities of Aminophylline. Approved, Investigational Mexiletine The metabolism of Aminophylline can be decreased when combined with Mexiletine. Approved Midazolam The therapeutic efficacy of Midazolam can be decreased when used in combination with Aminophylline. Approved, Illicit Mifepristone The serum concentration of Aminophylline can be increased when it is combined with Mifepristone. Approved, Investigational Mitotane The serum concentration of Aminophylline can be decreased when it is combined with Mitotane. Approved Modafinil The serum concentration of Aminophylline can be decreased when it is combined with Modafinil. Approved, Investigational Moexipril The serum concentration of Aminophylline can be decreased when it is combined with Moexipril. Approved Moxifloxacin The metabolism of Aminophylline can be decreased when combined with Moxifloxacin. Approved, Investigational N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline The serum concentration of Aminophylline can be decreased when it is combined with N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline. Experimental Nadolol Nadolol may decrease the bronchodilatory activities of Aminophylline. Approved Nafamostat The serum concentration of Aminophylline can be decreased when it is combined with Nafamostat. Approved, Investigational Nafcillin The serum concentration of Aminophylline can be decreased when it is combined with Nafcillin. Approved Nalidixic Acid The metabolism of Aminophylline can be decreased when combined with Nalidixic Acid. Approved Natural alpha interferon The metabolism of Aminophylline can be decreased when combined with Natural alpha interferon. Approved, Investigational Nebivolol Nebivolol may decrease the bronchodilatory activities of Aminophylline. Approved, Investigational Nefazodone The metabolism of Aminophylline can be decreased when combined with Nefazodone. Approved, Withdrawn Nelfinavir The metabolism of Aminophylline can be decreased when combined with Nelfinavir. Approved Nemonoxacin The metabolism of Aminophylline can be decreased when combined with Nemonoxacin. Investigational Netazepide The therapeutic efficacy of Netazepide can be decreased when used in combination with Aminophylline. Investigational Netupitant The serum concentration of Aminophylline can be increased when it is combined with Netupitant. Approved Nevirapine The metabolism of Aminophylline can be increased when combined with Nevirapine. Approved Nicotine The metabolism of Aminophylline can be decreased when combined with Nicotine. Approved Nilotinib The metabolism of Aminophylline can be decreased when combined with Nilotinib. Approved, Investigational Nitrazepam The therapeutic efficacy of Nitrazepam can be decreased when used in combination with Aminophylline. Approved Nitroaspirin The serum concentration of Aminophylline can be decreased when it is combined with Nitroaspirin. Investigational Norfloxacin The metabolism of Aminophylline can be decreased when combined with Norfloxacin. Approved Ofloxacin The metabolism of Aminophylline can be decreased when combined with Ofloxacin. Approved Olaparib The metabolism of Aminophylline can be decreased when combined with Olaparib. Approved Oleandomycin The metabolism of Aminophylline can be decreased when combined with Oleandomycin. Vet Approved Olodaterol The risk or severity of adverse effects can be increased when Aminophylline is combined with Olodaterol. Approved Omapatrilat The serum concentration of Aminophylline can be decreased when it is combined with Omapatrilat. Investigational Osimertinib The serum concentration of Aminophylline can be increased when it is combined with Osimertinib. Approved Otamixaban The serum concentration of Aminophylline can be decreased when it is combined with Otamixaban. Investigational Oxazepam The therapeutic efficacy of Oxazepam can be decreased when used in combination with Aminophylline. Approved Oxprenolol Oxprenolol may decrease the bronchodilatory activities of Aminophylline. Approved Palbociclib The serum concentration of Aminophylline can be increased when it is combined with Palbociclib. Approved Pancuronium The risk or severity of adverse effects can be increased when Aminophylline is combined with Pancuronium. Approved Pazufloxacin The metabolism of Aminophylline can be decreased when combined with Pazufloxacin. Investigational Pefloxacin The metabolism of Aminophylline can be decreased when combined with Pefloxacin. Approved Peginterferon alfa-2a The metabolism of Aminophylline can be decreased when combined with Peginterferon alfa-2a. Approved, Investigational Peginterferon alfa-2b The serum concentration of Aminophylline can be increased when it is combined with Peginterferon alfa-2b. Approved Peginterferon beta-1a The metabolism of Aminophylline can be decreased when combined with Peginterferon beta-1a. Approved Penbutolol Penbutolol may decrease the bronchodilatory activities of Aminophylline. Approved, Investigational Pentobarbital The metabolism of Aminophylline can be increased when combined with Pentobarbital. Approved, Vet Approved Pentoxifylline The serum concentration of Aminophylline can be increased when it is combined with Pentoxifylline. Approved, Investigational Perindopril The serum concentration of Aminophylline can be decreased when it is combined with Perindopril. Approved PF-477736 The therapeutic efficacy of Pf 00477736 can be decreased when used in combination with Aminophylline. Investigational Phenobarbital The metabolism of Aminophylline can be increased when combined with Phenobarbital. Approved Phenytoin The serum concentration of Aminophylline can be decreased when it is combined with Phenytoin. Approved, Vet Approved Phosphoramidon The serum concentration of Aminophylline can be decreased when it is combined with Phosphoramidon. Experimental Pindolol Pindolol may decrease the bronchodilatory activities of Aminophylline. Approved Pirenzepine The therapeutic efficacy of Pirenzepine can be decreased when used in combination with Aminophylline. Approved Polyestradiol phosphate The serum concentration of Aminophylline can be increased when it is combined with Polyestradiol phosphate. Approved Posaconazole The metabolism of Aminophylline can be decreased when combined with Posaconazole. Approved, Investigational, Vet Approved Prazepam The therapeutic efficacy of Prazepam can be decreased when used in combination with Aminophylline. Approved, Illicit Primidone The metabolism of Aminophylline can be increased when combined with Primidone. Approved, Vet Approved Prinomastat The serum concentration of Aminophylline can be decreased when it is combined with Prinomastat. Investigational Probenecid The serum concentration of Aminophylline can be increased when it is combined with Probenecid. Approved Promestriene The serum concentration of Aminophylline can be increased when it is combined with Promestriene. Investigational Propafenone The serum concentration of Aminophylline can be increased when it is combined with Propafenone. Approved Propranolol Propranolol may decrease the bronchodilatory activities of Aminophylline. Approved, Investigational Propylthiouracil The serum concentration of Aminophylline can be increased when it is combined with Propylthiouracil. Approved Prulifloxacin The metabolism of Aminophylline can be decreased when combined with Prulifloxacin. Investigational Quinapril The serum concentration of Aminophylline can be decreased when it is combined with Quinapril. Approved, Investigational Quinestrol The serum concentration of Aminophylline can be increased when it is combined with Quinestrol. Approved Quinine The serum concentration of Aminophylline can be increased when it is combined with Quinine. Approved Racecadotril The serum concentration of Aminophylline can be decreased when it is combined with Racecadotril. Investigational Ramipril The serum concentration of Aminophylline can be decreased when it is combined with Ramipril. Approved Ranolazine The metabolism of Aminophylline can be decreased when combined with Ranolazine. Approved, Investigational Regadenoson Aminophylline may decrease the vasodilatory activities of Regadenoson. Approved Remikiren The serum concentration of Aminophylline can be decreased when it is combined with Remikiren. Approved Rifabutin The metabolism of Aminophylline can be increased when combined with Rifabutin. Approved Rifampicin The metabolism of Aminophylline can be increased when combined with Rifampicin. Approved Rifapentine The metabolism of Aminophylline can be increased when combined with Rifapentine. Approved Riociguat Aminophylline may increase the hypotensive activities of Riociguat. Approved Ritonavir The metabolism of Aminophylline can be decreased when combined with Ritonavir. Approved, Investigational Rivaroxaban The serum concentration of Aminophylline can be decreased when it is combined with Rivaroxaban. Approved Ropinirole The metabolism of Aminophylline can be decreased when combined with Ropinirole. Approved, Investigational Rosoxacin The metabolism of Aminophylline can be decreased when combined with Rosoxacin. Approved Saquinavir The metabolism of Aminophylline can be decreased when combined with Saquinavir. Approved, Investigational Saxagliptin The serum concentration of Aminophylline can be decreased when it is combined with Saxagliptin. Approved Secobarbital The serum concentration of Aminophylline can be decreased when it is combined with Secobarbital. Approved, Vet Approved Secoisolariciresinol The serum concentration of Aminophylline can be increased when it is combined with Secoisolariciresinol. Investigational Sildenafil The metabolism of Aminophylline can be decreased when combined with Sildenafil. Approved, Investigational Siltuximab The serum concentration of Aminophylline can be decreased when it is combined with Siltuximab. Approved Simeprevir The serum concentration of Aminophylline can be increased when it is combined with Simeprevir. Approved Sitagliptin The serum concentration of Aminophylline can be decreased when it is combined with Sitagliptin. Approved, Investigational Solithromycin The metabolism of Aminophylline can be decreased when combined with Solithromycin. Investigational Sotalol Sotalol may decrease the bronchodilatory activities of Aminophylline. Approved Sparfloxacin The metabolism of Aminophylline can be decreased when combined with Sparfloxacin. Approved Spirapril The serum concentration of Aminophylline can be decreased when it is combined with Spirapril. Approved St. John's Wort The serum concentration of Aminophylline can be decreased when it is combined with St. John's Wort. Nutraceutical Stiripentol The serum concentration of Aminophylline can be increased when it is combined with Stiripentol. Approved Sulfisoxazole The metabolism of Aminophylline can be decreased when combined with Sulfisoxazole. Approved, Vet Approved Synthetic Conjugated Estrogens, A The serum concentration of Aminophylline can be increased when it is combined with Synthetic Conjugated Estrogens, A. Approved Synthetic Conjugated Estrogens, B The serum concentration of Aminophylline can be increased when it is combined with Synthetic Conjugated Estrogens, B. Approved Telaprevir The metabolism of Aminophylline can be decreased when combined with Telaprevir. Withdrawn Telithromycin The metabolism of Aminophylline can be decreased when combined with Telithromycin. Approved Temafloxacin The metabolism of Aminophylline can be decreased when combined with Temafloxacin. Withdrawn Temazepam The therapeutic efficacy of Temazepam can be decreased when used in combination with Aminophylline. Approved Temocapril The serum concentration of Aminophylline can be decreased when it is combined with Temocapril. Experimental, Investigational Tenofovir disoproxil The metabolism of Aminophylline can be decreased when combined with Tenofovir. Approved, Investigational Teriflunomide The serum concentration of Aminophylline can be decreased when it is combined with Teriflunomide. Approved Theophylline The metabolism of Aminophylline can be decreased when combined with Theophylline. Approved Thiabendazole The metabolism of Aminophylline can be decreased when combined with Thiabendazole. Approved, Vet Approved Thiamylal The serum concentration of Aminophylline can be decreased when it is combined with Thiamylal. Approved, Vet Approved Thiopental The therapeutic efficacy of Thiopental can be decreased when used in combination with Aminophylline. Approved, Vet Approved Thiorphan The serum concentration of Aminophylline can be decreased when it is combined with Thiorphan. Experimental Thyroid, porcine The metabolism of Aminophylline can be increased when combined with Thyroid, porcine. Approved Tibolone The serum concentration of Aminophylline can be increased when it is combined with Tibolone. Approved Ticlopidine The metabolism of Aminophylline can be decreased when combined with Ticlopidine. Approved Timolol Timolol may decrease the bronchodilatory activities of Aminophylline. Approved Tipranavir The serum concentration of Aminophylline can be decreased when it is combined with Tipranavir. Approved, Investigational Tizanidine The serum concentration of Tizanidine can be increased when it is combined with Aminophylline. Approved Tocilizumab The serum concentration of Aminophylline can be decreased when it is combined with Tocilizumab. Approved Trandolapril The serum concentration of Aminophylline can be decreased when it is combined with Trandolapril. Approved Triazolam The therapeutic efficacy of Triazolam can be decreased when used in combination with Aminophylline. Approved Trovafloxacin The metabolism of Aminophylline can be decreased when combined with Trovafloxacin. Approved, Withdrawn Tylosin The metabolism of Aminophylline can be decreased when combined with Tylosin. Vet Approved Ubenimex The serum concentration of Aminophylline can be decreased when it is combined with Ubenimex. Experimental Ulinastatin The serum concentration of Aminophylline can be decreased when it is combined with Ulinastatin. Investigational Vemurafenib The serum concentration of Aminophylline can be increased when it is combined with Vemurafenib. Approved Venlafaxine The metabolism of Aminophylline can be decreased when combined with Venlafaxine. Approved Verapamil The metabolism of Aminophylline can be decreased when combined with Verapamil. Approved Vildagliptin The serum concentration of Aminophylline can be decreased when it is combined with Vildagliptin. Approved, Investigational Voriconazole The metabolism of Aminophylline can be decreased when combined with Voriconazole. Approved, Investigational Ximelagatran The serum concentration of Aminophylline can be decreased when it is combined with Ximelagatran. Approved, Investigational, Withdrawn Zafirlukast The serum concentration of Zafirlukast can be decreased when it is combined with Aminophylline. Approved, Investigational Zeranol The serum concentration of Aminophylline can be increased when it is combined with Zeranol. Vet Approved Ziprasidone The metabolism of Aminophylline can be decreased when combined with Ziprasidone. Approved - Food Interactions
- Limit caffeine intake.
- Take with food.
- Vitamin B6 needs increased, supplement recommended.
References
- Synthesis Reference
- Not Available
- General References
- Not Available
- External Links
- Human Metabolome Database
- HMDB15354
- KEGG Drug
- D00227
- PubChem Compound
- 9433
- PubChem Substance
- 46508784
- ChemSpider
- 9062
- ChEBI
- 2659
- ChEMBL
- CHEMBL1370561
- Therapeutic Targets Database
- DAP000613
- PharmGKB
- PA164781029
- Drugs.com
- Drugs.com Drug Page
- Wikipedia
- Aminophylline
- ATC Codes
- R03DA20 — Combinations of xanthines
- R03DA — Xanthines
- R03D — OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
- R03 — DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
- R — RESPIRATORY SYSTEM
- R03DA — Xanthines
- R03D — OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
- R03 — DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
- R — RESPIRATORY SYSTEM
- R03DB — Xanthines and adrenergics
- R03D — OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
- R03 — DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
- R — RESPIRATORY SYSTEM
- AHFS Codes
- 86:16.00
- PDB Entries
- Not Available
- FDA label
- Not Available
- MSDS
- Download (72.7 KB)
Clinical Trials
- Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Amend
- C.O. Truxton Inc.
- Cardinal Health
- Carlisle Laboratories Inc.
- Dispensing Solutions
- G & W Labs
- General Injectables and Vaccines Inc.
- Hospira Inc.
- Kaiser Foundation Hospital
- Lake Erie Medical and Surgical Supply
- Major Pharmaceuticals
- Murfreesboro Pharmaceutical Nursing Supply
- PCA LLC
- Pharmedix
- Prescript Pharmaceuticals
- West-Ward Pharmaceuticals
- Dosage forms
Form Route Strength Injection, solution Intravenous 25 mg/mL Tablet Oral 100 mg/1 Tablet Oral 200 mg/1 Liquid Intravenous 25 mg Solution Intravenous 25 mg Solution Intravenous 50 mg Tablet Oral 100 mg Tablet Oral 97.5 mg Tablet, extended release Oral 225 mg Tablet, extended release Oral 350 mg - Prices
Unit description Cost Unit Aminophylline 250 mg/10 ml vial 0.48USD ml Aminophylline 25 mg/ml 0.41USD ml Phyllocontin-350 350 mg Sustained-Release Tablet 0.31USD tablet Aminophylline 100 mg tablet 0.26USD tablet Phyllocontin 225 mg Sustained-Release Tablet 0.24USD tablet Aminophylline powder 0.17USD g Aminophylline 200 mg tablet 0.15USD tablet DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source water solubility 2E+005 mg/L MERCK INDEX (1996) logP -3.03 Not Available - Predicted Properties
Property Value Source logP -0.77 ChemAxon pKa (Strongest Acidic) 7.82 ChemAxon pKa (Strongest Basic) -0.78 ChemAxon Physiological Charge 0 ChemAxon Hydrogen Acceptor Count 3 ChemAxon Hydrogen Donor Count 1 ChemAxon Polar Surface Area 69.3 Å2 ChemAxon Rotatable Bond Count 1 ChemAxon Refractivity 44.93 m3·mol-1 ChemAxon Polarizability 16.86 Å3 ChemAxon Number of Rings 4 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter No ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET features
Property Value Probability Human Intestinal Absorption + 0.9778 Blood Brain Barrier + 0.5908 Caco-2 permeable - 0.6802 P-glycoprotein substrate Substrate 0.7341 P-glycoprotein inhibitor I Non-inhibitor 0.9164 P-glycoprotein inhibitor II Non-inhibitor 0.9673 Renal organic cation transporter Non-inhibitor 0.7935 CYP450 2C9 substrate Non-substrate 0.8073 CYP450 2D6 substrate Non-substrate 0.8093 CYP450 3A4 substrate Substrate 0.5482 CYP450 1A2 substrate Non-inhibitor 0.8726 CYP450 2C9 inhibitor Non-inhibitor 0.9332 CYP450 2D6 inhibitor Non-inhibitor 0.9633 CYP450 2C19 inhibitor Non-inhibitor 0.9184 CYP450 3A4 inhibitor Non-inhibitor 0.8031 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.8858 Ames test Non AMES toxic 0.6724 Carcinogenicity Non-carcinogens 0.8696 Biodegradation Not ready biodegradable 0.9149 Rat acute toxicity 2.4979 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.7876 hERG inhibition (predictor II) Inhibitor 0.6143
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key LC-MS/MS Spectrum - LC-ESI-qTof , Positive LC-MS/MS Not Available LC-MS/MS Spectrum - , positive LC-MS/MS splash10-001i-1900000000-f6d60952fa154f363515 Predicted LC-MS/MS Spectrum - 10V, Positive Predicted LC-MS/MS Not Available Predicted LC-MS/MS Spectrum - 20V, Positive Predicted LC-MS/MS Not Available Predicted LC-MS/MS Spectrum - 40V, Positive Predicted LC-MS/MS Not Available Predicted LC-MS/MS Spectrum - 10V, Negative Predicted LC-MS/MS Not Available Predicted LC-MS/MS Spectrum - 20V, Negative Predicted LC-MS/MS Not Available Predicted LC-MS/MS Spectrum - 40V, Negative Predicted LC-MS/MS Not Available
Taxonomy
- Description
- This compound belongs to the class of chemical entities known as monoalkylamines. These are organic compounds containing an primary aliphatic amine group.
- Kingdom
- Chemical entities
- Super Class
- Organic compounds
- Class
- Organic nitrogen compounds
- Sub Class
- Organonitrogen compounds
- Direct Parent
- Monoalkylamines
- Alternative Parents
- Organopnictogen compounds / Hydrocarbon derivatives
- Substituents
- Organopnictogen compound / Hydrocarbon derivative / Primary aliphatic amine / Aromatic heteropolycyclic compound
- Molecular Framework
- Not Available
- External Descriptors
- Not Available
Targets
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Metal ion binding
- Specific Function
- Cyclic nucleotide phosphodiesterase with a dual-specificity for the second messengers cAMP and cGMP, which are key regulators of many important physiological processes.
- Gene Name
- PDE3A
- Uniprot ID
- Q14432
- Uniprot Name
- cGMP-inhibited 3',5'-cyclic phosphodiesterase A
- Molecular Weight
- 124978.06 Da
References
- Hirota K, Yoshioka H, Kabara S, Koizumi Y, Abe H, Sato T, Matsuki A: Spasmolytic effects of colforsin daropate on serotonin-induced pulmonary hypertension and bronchoconstriction in dogs. Acta Anaesthesiol Scand. 2002 Mar;46(3):297-302. [PubMed:11939921 ]
- Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Antagonist
- General Function
- Purine nucleoside binding
- Specific Function
- Receptor for adenosine. The activity of this receptor is mediated by G proteins which inhibit adenylyl cyclase.
- Gene Name
- ADORA1
- Uniprot ID
- P30542
- Uniprot Name
- Adenosine receptor A1
- Molecular Weight
- 36511.325 Da
References
- Yamamoto S, Nakanishi O, Matsui T, Shinohara N, Kinoshita H, Lambert C, Ishikawa T: Intrathecal adenosine A1 receptor agonist attenuates hyperalgesia without inhibiting spinal glutamate release in the rat. Cell Mol Neurobiol. 2003 Apr;23(2):175-85. [PubMed:12735630 ]
- Lerman BB: Response of nonreentrant catecholamine-mediated ventricular tachycardia to endogenous adenosine and acetylcholine. Evidence for myocardial receptor-mediated effects. Circulation. 1993 Feb;87(2):382-90. [PubMed:8425287 ]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Antagonist
- General Function
- G-protein coupled adenosine receptor activity
- Specific Function
- Receptor for adenosine. The activity of this receptor is mediated by G proteins which inhibits adenylyl cyclase. Possible role in reproduction.
- Gene Name
- ADORA3
- Uniprot ID
- P0DMS8
- Uniprot Name
- Adenosine receptor A3
- Molecular Weight
- 36184.175 Da
References
- Stella L, de Novellis V, Marabese I, Berrino L, Maione S, Filippelli A, Rossi F: The role of A3 adenosine receptors in central regulation of arterial blood pressure. Br J Pharmacol. 1998 Oct;125(3):437-40. [PubMed:9806324 ]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Activator
- General Function
- Transcription factor binding
- Specific Function
- Responsible for the deacetylation of lysine residues on the N-terminal part of the core histones (H2A, H2B, H3 and H4). Histone deacetylation gives a tag for epigenetic repression and plays an impo...
- Gene Name
- HDAC2
- Uniprot ID
- Q92769
- Uniprot Name
- Histone deacetylase 2
- Molecular Weight
- 55363.855 Da
References
- Ito K, Lim S, Caramori G, Cosio B, Chung KF, Adcock IM, Barnes PJ: A molecular mechanism of action of theophylline: Induction of histone deacetylase activity to decrease inflammatory gene expression. Proc Natl Acad Sci U S A. 2002 Jun 25;99(13):8921-6. Epub 2002 Jun 17. [PubMed:12070353 ]
Enzymes
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- SubstrateInhibitor
- General Function
- Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
- Gene Name
- CYP1A2
- Uniprot ID
- P05177
- Uniprot Name
- Cytochrome P450 1A2
- Molecular Weight
- 58293.76 Da
References
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Steroid hydroxylase activity
- Specific Function
- Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic ...
- Gene Name
- CYP2E1
- Uniprot ID
- P05181
- Uniprot Name
- Cytochrome P450 2E1
- Molecular Weight
- 56848.42 Da
References
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Vitamin d3 25-hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
- Gene Name
- CYP3A4
- Uniprot ID
- P08684
- Uniprot Name
- Cytochrome P450 3A4
- Molecular Weight
- 57342.67 Da
References
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Drug created on June 13, 2005 07:24 / Updated on September 01, 2017 10:37